enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Up 400.0% in March

enGene Holdings Inc. (NASDAQ:ENGNWGet Free Report) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 16,000 shares, an increase of 400.0% from the February 29th total of 3,200 shares. Based on an average daily volume of 39,600 shares, the short-interest ratio is presently 0.4 days.

enGene Stock Performance

Shares of enGene stock opened at $5.20 on Friday. The company has a 50 day moving average of $3.17. enGene has a 52 week low of $0.39 and a 52 week high of $6.50.

About enGene

(Get Free Report)

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

Featured Stories

Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.